These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. On the etiology of subcapsular lenticular opacities produced in dogs receiving HMG-CoA reductase inhibitors. Gerson RJ; MacDonald JS; Alberts AW; Chen J; Yudkovitz JB; Greenspan MD; Rubin LF; Bokelman DL Exp Eye Res; 1990 Jan; 50(1):65-78. PubMed ID: 2307197 [TBL] [Abstract][Full Text] [Related]
11. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors. Yang SH; Choi JS; Choi DH Pharmacology; 2011; 88(1-2):1-9. PubMed ID: 21709429 [TBL] [Abstract][Full Text] [Related]
12. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Hsu I; Spinler SA; Johnson NE Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093 [TBL] [Abstract][Full Text] [Related]
13. Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans. Pentikainen PJ; Saraheimo M; Schwartz JI; Amin RD; Schwartz MS; Brunner-Ferber F; Rogers JD J Clin Pharmacol; 1992 Feb; 32(2):136-40. PubMed ID: 1613123 [TBL] [Abstract][Full Text] [Related]
14. HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture. Flint OP; Masters BA; Gregg RE; Durham SK Toxicol Appl Pharmacol; 1997 Jul; 145(1):99-110. PubMed ID: 9221829 [TBL] [Abstract][Full Text] [Related]
15. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Garnett WR Am J Health Syst Pharm; 1995 Aug; 52(15):1639-45. PubMed ID: 7583826 [TBL] [Abstract][Full Text] [Related]